The mucormycosis market size is USD 582.6 Mn in 2026.
The mucormycosis market is projected to grow at a CAGR of 3% by 2033.
The mucormycosis market growth is driven by rising diabetes prevalence, increasing transplant procedures, and a growing immunocompromised population.
Europe is a dominating region for the mucormycosis market.
Pfizer Inc., Gilead Sciences, Inc., Merck & Co., Inc., Novartis AG, and Abbott Laboratories are some leading industry players in the mucormycosis market.